Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells

Biomedicine and Pharmacotherapy

Volumn 68, Issue 1, 2014, Pages 31-37

  Xie, Fang Wei ^a   Peng, Yong Hai ^a   Chen, Xi ^a   Chen, Xiong ^a   Li, Jie ^a   Yu, Zong Yang ^a   Wang, Wen Wu ^a   Ouyang, Xue Nong ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Aberrant methylation; CES2; Colorectal cancer cell; CPT 11; Gene expression; GUSB; UGT1A1

Indexed keywords

ABERRANT METHYLATION; CES2; COLORECTAL CANCER CELL; CPT-11; GENE EXPRESSION; GUSB; UGT1A1;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; COLORECTAL NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUCURONIDASE; GLUCURONOSYLTRANSFERASE; HUMANS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84895071520     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.06.013     Document Type: Article

References (30)

1. Xu G., Zhang W., Ma M.K., et al. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002, 8:2605-2611.
2. Ohtsuka K., Inoue S., Kameyama M., et al. Intracellular conversion of irinotecan to its active form, sn-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer 2003, 41:187-198.
3. Sanghani S.P., Quinney S.K., Fredenburg T.B., et al. Carboxylesterases expressed in human colon tumor tissue and their role in cpt-11 hydrolysis. Clin Cancer Res 2003, 9:4983-4991.
4. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400.
5. Eden A., Gaudet F., Waghmare A., et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455-456.
6. Gaudet F., Hodgson J.G., Eden A., et al. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
7. Lengauer C. An unstable liaison. Science 2003, 300:442-443.
8. Asano T., Nakamura K., Fujii H., et al. Altered expression of topoisomerase iiα contributes to cross-resistant to etoposide k562/mx2 cell line by aberrant methylation. Br J Cancer 2005, 92:1486-1492.
9. Lu R., Fang J.Y. Epigenetic modification and cancer. Chin Bull Life Sci 2006, 18.
10. Strathdee G., MacKean M., Illand M., et al. A role for methylation of the hmlh1 promoter in loss of hmlh1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18:2335.
11. Lin C.H., Hsieh S.Y., Sheen I.S., et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001, 61:4238-4243.
12. Ying J., Li H., Seng T.J., et al. Functional epigenetics identifies a protocadherin pcdh10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2005, 25:1070-1080.
13. Fukutomi S., Seki N., Koda K., et al. Identification of methylation-silenced genes in colorectal cancer cell lines: Genomic screening using oligonucleotide arrays. Scandinav J Gastroenterol 2007, 42:1486-1494.
14. Eads C.A., Lord R.V., Kurumboor S.K., et al. Fields of aberrant cpg island hypermethylation in barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60:5021-5026.
15. Pavillard V., Agostini C., Richard S., et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 2002, 49:329-335.
16. Wierdl M., Tsurkan L., Hyatt J., et al. An improved human carboxylesterase for enzyme/prodrug therapy with cpt-11. Cancer Gene Ther 2008, 15:183-192.
17. Oosterhoff D., Overmeer R.M., de Graaf M., et al. Adenoviral vector-mediated expression of a gene encoding secreted, epcam-targeted carboxylesterase-2 sensitises colon cancer spheroids to cpt-11. Br J Cancer 2005, 92:882-887.
18. Fujiwara R., Nakajima M., Yamanaka H., et al. Interactions between human ugt1a1, ugt1a4, and ugt1a6 affect their enzymatic activities. Drug Metab Dispos 2007, 35:1781-1787.
19. Tobin P., Clarke S., Seale J.P., et al. The in vitro metabolism of irinotecan (cpt-11) by carboxylesterase and β-glucuronidase in human colorectal tumours. Br J Clin Pharmacol 2006, 62:122-129.
20. Baguley B., Marshall E. in vitro modelling of human tumour behaviour in drug discovery programmes. Eur J Cancer 2004, 40:794-801.
21. Hamilton SR: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008, 21:S23-S30.
22. Costello J.F., Plass C. Methylation matters. J Med Genet 2001, 38:285-303.
23. Bird A. The essentials of DNA methylation. Cell 1992, 70:5.
24. Zhang A., Xing Q., Qin S., et al. Intra-ethnic differences in genetic variants of the ugt-glucuronosyltransferase 1a1 gene in Chinese populations. Pharmacogenomics J 2006, 7:333-338.
25. Jun-xiao Z., Chen-liang W., et al. Relationship between ugt1a1 gene polymorphisms and toxicity/efficacy of irinotecan-based chemotherapy in metastatic colorectal cancer. Chin J Pathophysiol 2012, 5:012.
26. Yan P.S., Shi H., Rahmatpanah F., et al. Differential distribution of DNA methylation within the rassf1a cpg island in breast cancer. Cancer Res 2003, 63:6178-6186.
27. Hagihara A., Miyamoto K., Furuta J., et al. Identification of 27 5' cpg islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004, 23:8705-8710.
28. Song J.Z., Stirzaker C., Harrison J., et al. Hypermethylation trigger of the glutathione-s-transferase gene (gstp1) in prostate cancer cells. Oncogene 2002, 21:1048.
29. De Smet C., Loriot A., Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene mage-a1 in tumor cells. Mol Cell Biol 2004, 24:4781-4790.
30. Stirzaker C., Song J.Z., Davidson B., et al. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004, 64:3871-3877.